
CANF Stock Forecast & Price Target
CANF Analyst Ratings
Bulls say
Can Fite Biopharma is expected to have a positive outlook due to its strong pipeline of drugs targeting a novel mechanism through the A3 adenosine receptor, which is highly expressed in cancer and inflammatory cells. Their latest results in mPDAC demonstrate strong potential, and with multiple drugs in Phase II and III trials, it appears that Can Fite has a diverse portfolio that mitigates some risk. Additionally, with a discounted cash flow analysis and net pro forma cash added, the valuation of Can Fite looks promising. However, risks such as competition and dilution should be considered.
Bears say
Can Fite Biopharma is in a challenging financial situation as it reported FY2025 revenues of only $405K and a net loss of $5.97 per diluted share. Despite some favorable clinical data in its Phase 2a study for pancreatic cancer, the company will need significant funding to pursue its combination immunotherapy strategy for the indication and has no revenues projected for 2026. Management has disclosed confidentiality agreements for potential partnerships, but until a partnership is secured, Can Fite Biopharma's financial outlook remains uncertain and reliant on additional capital raises.
This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.
CANF Analyst Forecast & Price Prediction
Start investing in CANF
Order type
Buy in
Order amount
Est. shares
0 shares